Tofacitinib for the treatment of active ankylosing spondylitis in adults

References

• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Dougados M, et al. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1(1):15013.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, and Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285–1299 .
   PubMed Web of Science ®Google Scholar
• Akkoc N, and Khan MA. JAK inhibitors for axial spondyloarthritis: what does the future hold?. Curr Rheumatol Rep. 2021;23(6):34.
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Mol Med Rep. 2017;15(4):1943–1951.
   PubMed Web of Science ®Google Scholar
• Hanson A, Brown MA. Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am. 2017;43(3):401–414.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Brown MA. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):539–553.
   PubMed Web of Science ®Google Scholar
• Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15(1):489.
   PubMed Web of Science ®Google Scholar
• Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, et al. Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol. 2015;67(11):2813–2827.
   PubMed Web of Science ®Google Scholar
• Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19(1):51.
   PubMedGoogle Scholar
• Valeri M, Raffatellu M, Napier B. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74(9). DOI:https://doi.org/10.1093/femspd/ftw111
   Google Scholar
• Sonnenberg GF, Artis D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity. 2012;37(4):601–610.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.
   PubMed Web of Science ®Google Scholar
• Hammitzsch A, Lorenz G, Moog P. Impact of Janus Kinase inhibition on the treatment of axial spondyloarthropathies. Front Immunol. 2020;11:591176.
   PubMed Web of Science ®Google Scholar
• Veale DJ, McGonagle D, and McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019;58(2):197–205.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. Bmj. 2021;372:m4447.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–546.
   PubMed Web of Science ®Google Scholar
• Labs P, Editor. Xeljanz (Tofacitinib). New York (NY); 2018.
   Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology. 2018;57(8):1390–1399.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Sliwinska-Stanczyk P, and Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004–1013.
   PubMed Web of Science ®Google Scholar
• Adapted from “FullTemplateName”, by BioRender.com (CurrentYear). Available from: https://app.biorender.com/biorender-templates.
   Google Scholar
• Deodhar A, Chakravarty SD, Cameron C, et al. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020;39(8):2307–2315.
   PubMed Web of Science ®Google Scholar
• Inc P. Pfizer shares co-primary endpoint results from post-marketing required safety study of xeljanz® (Tofacitinib) in subjects with rheumatoid arthritis (RA), in ORAL surveillance study results; 2021.
   Google Scholar
• Van Der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–2387.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Song I-H, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108–2117.
   PubMed Web of Science ®Google Scholar
• FDA. FDA drug safety communication, in FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; 2021.
   Google Scholar
• Feagan B. Update on tofacitinib for inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(9):572–574.
   Google Scholar
• Rogler G. Efficacy of JAK inhibitors in Crohn’s disease. J Crohns Colitis. 2020;14(Supplement_2):S746–s754.
   PubMedGoogle Scholar